Supplemental Figure 1: Patient disposition (all women).

AE, adverse event; b.i.d., twice daily; ITT, intent-to-treat.

All randomized patients (N=2939)

ITT population: Randomized to tegaserod 6 mg b.i.d. (n=1478)

Safety population: (n=1477)

Discontinued (n=268)
- AE(s), n=97 (6.6%)
- Patient withdrew consent, n=84 (5.7%)
- Lost to follow-up, n=40 (2.7%)
- Unsatisfactory therapeutic effect, n=24 (1.6%)
- Protocol violation, n=12 (0.8%)
- Abnormal laboratory value(s), n=7 (0.5%)
- Administrative problems, n=4 (0.3%)

Completed study (n=1210)

ITT population: Randomized to placebo b.i.d. (n=1459)

Safety population: (n=1364)

Discontinued (n=286)
- AE(s), n=74 (5.1%)
- Patient withdrew consent, n=86 (5.9%)
- Lost to follow-up, n=57 (3.9%)
- Unsatisfactory therapeutic effect, n=49 (3.4%)
- Protocol violation, n=10 (0.7%)
- Abnormal laboratory value(s), n=5 (0.3%)
- Administrative problems, n=4 (0.3%)
- Patient condition no longer requires study drug, n=1 (0.1%)

Completed study (n=1175)